{"log_id": 3734658901988827143, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 1e-06, "average": 0.9991, "min": 0.996237}, "location": {"width": 467, "top": 160, "height": 48, "left": 206}, "words": "未对儿童使用吉西他滨进行研究,因此儿童应慎用"}, {"probability": {"variance": 0, "average": 0.963027, "min": 0.963027}, "location": {"width": 30, "top": 156, "height": 28, "left": 1140}, "words": "品"}, {"probability": {"variance": 9e-06, "average": 0.998357, "min": 0.983979}, "location": {"width": 802, "top": 200, "height": 65, "left": 207}, "words": "65岁以上的老年患者耐受性未见明显变化,尽管年龄对吉西他滨的清除率和半衰期有影"}, {"probability": {"variance": 2.3e-05, "average": 0.991617, "min": 0.98392}, "location": {"width": 118, "top": 206, "height": 27, "left": 203}, "words": "【老年用药】"}, {"probability": {"variance": 0.053155, "average": 0.586513, "min": 0.355959}, "location": {"width": 48, "top": 195, "height": 27, "left": 1130}, "words": "晶"}, {"probability": {"variance": 7e-06, "average": 0.997355, "min": 0.991851}, "location": {"width": 422, "top": 248, "height": 45, "left": 178}, "words": "响,但并没有证据表明高龄患者需要调整剂量"}, {"probability": {"variance": 1.2e-05, "average": 0.995773, "min": 0.98868}, "location": {"width": 161, "top": 285, "height": 34, "left": 205}, "words": "【药物相互作用】"}, {"probability": {"variance": 3e-05, "average": 0.997382, "min": 0.969075}, "location": {"width": 762, "top": 289, "height": 61, "left": 250}, "words": "吉西他滨与其他的抗肿瘤药物配伍进行联合或序贯化疗时,应考虑对骨髓抑制作用"}, {"probability": {"variance": 2e-06, "average": 0.99866, "min": 0.996619}, "location": {"width": 65, "top": 363, "height": 26, "left": 180}, "words": "的蓄积"}, {"probability": {"variance": 1e-06, "average": 0.998199, "min": 0.997068}, "location": {"width": 56, "top": 399, "height": 23, "left": 254}, "words": "放疗"}, {"probability": {"variance": 0.000224, "average": 0.994078, "min": 0.915896}, "location": {"width": 763, "top": 402, "height": 60, "left": 253}, "words": "同步放化疗(放化疗一起应用或者不同治疗间的间隔≤7天)一与这种多途径治疗相"}, {"probability": {"variance": 0.000168, "average": 0.996207, "min": 0.916921}, "location": {"width": 833, "top": 438, "height": 64, "left": 183}, "words": "关的毒性取决于许多不同的因素,包括吉西他滨的剂量、吉西他滨的给药频率、放射治疗的"}, {"probability": {"variance": 0.000367, "average": 0.994115, "min": 0.884808}, "location": {"width": 834, "top": 476, "height": 64, "left": 183}, "words": "剂量、放疗采用的技术、靶组织和靶用量等等。临床前研究和临床研究显示,吉西他滨具有"}, {"probability": {"variance": 7.4e-05, "average": 0.995595, "min": 0.962259}, "location": {"width": 835, "top": 513, "height": 64, "left": 185}, "words": "放疗增敏作用。在一个单项研究中,非小细胞肺癌患者在连续6周内同时接受剂量为1,000"}, {"probability": {"variance": 0.000147, "average": 0.995429, "min": 0.934623}, "location": {"width": 833, "top": 550, "height": 65, "left": 187}, "words": "mg/m2的吉西他滨治疗和胸部治疗性放疗,研究中观察到患者出现严重的、具有潜在致命性"}, {"probability": {"variance": 0.000112, "average": 0.99487, "min": 0.943553}, "location": {"width": 821, "top": 588, "height": 64, "left": 195}, "words": "的粘膜炎,特别是食道炎和肺炎,正在接受大剂量放疗的患者尤其如此[中位治疗量4,795"}, {"probability": {"variance": 0.007341, "average": 0.972788, "min": 0.560587}, "location": {"width": 809, "top": 627, "height": 62, "left": 192}, "words": "m3]。此后进行的研究(如非小细胞肺癌II期研究)表明,在有着可预测毒性的情况下"}, {"probability": {"variance": 2.7e-05, "average": 0.997347, "min": 0.97046}, "location": {"width": 830, "top": 662, "height": 65, "left": 191}, "words": "在进行放疗的同时给予相对低剂量的吉西他滨治疗也是可行的。在6周的时间里同时给予"}, {"probability": {"variance": 0.007105, "average": 0.974226, "min": 0.480449}, "location": {"width": 788, "top": 704, "height": 59, "left": 191}, "words": "剂量为66Gy的胸部放疗、吉西他滨(600mg/m2,4次)和顺铂(80mg/m2,2次)治疗"}, {"probability": {"variance": 0.005086, "average": 0.980762, "min": 0.538171}, "location": {"width": 832, "top": 738, "height": 62, "left": 195}, "words": "些期和II期研究显示,对非小细胞肺癌和胰腺癌可以同时给予放疗和剂量高达300mg/m2"}, {"probability": {"variance": 0.000189, "average": 0.995215, "min": 0.918558}, "location": {"width": 833, "top": 775, "height": 63, "left": 196}, "words": "周的吉西他滨单药治疗。对于所有的肿瘤类型,目前尚未确定出与治疗剂量放疗同时应用的"}, {"probability": {"variance": 1e-06, "average": 0.999311, "min": 0.996678}, "location": {"width": 278, "top": 836, "height": 40, "left": 196}, "words": "安全的最佳吉西他滨治疗方案"}, {"probability": {"variance": 0.011997, "average": 0.96304, "min": 0.455527}, "location": {"width": 759, "top": 889, "height": 59, "left": 271}, "words": "非同步放化疗(不同治疗间的时间间隔>7天)一数据分析显示,在放疗前后7天以上的"}, {"probability": {"variance": 0.010273, "average": 0.980726, "min": 0.351732}, "location": {"width": 830, "top": 925, "height": 64, "left": 202}, "words": "时间里应用吉西他滨治疗,不会使毒性增加,但能出现放射记忆反应。研究资料显示,吉"}, {"probability": {"variance": 0.006929, "average": 0.97413, "min": 0.548772}, "location": {"width": 685, "top": 967, "height": 59, "left": 202}, "words": "西他滨治疗应在放疗急性反应好转以后或者放疗结束至少1周之后才能进行"}, {"probability": {"variance": 0.000126, "average": 0.993963, "min": 0.948752}, "location": {"width": 760, "top": 1037, "height": 60, "left": 276}, "words": "目前已有靶组织出现放射损伤的报告(如,食道炎、大肠炎和肺炎),这些损伤与患"}, {"probability": {"variance": 5e-06, "average": 0.998425, "min": 0.990407}, "location": {"width": 406, "top": 1093, "height": 45, "left": 204}, "words": "者放疗时同时或不同时应用的吉西他滨相关"}, {"probability": {"variance": 1.1e-05, "average": 0.993423, "min": 0.990752}, "location": {"width": 119, "top": 1174, "height": 35, "left": 235}, "words": "【药物过量】"}, {"probability": {"variance": 0.00026, "average": 0.99452, "min": 0.898396}, "location": {"width": 762, "top": 1180, "height": 60, "left": 280}, "words": "对吉西他滨过量尚无解毒剂。曾有报告单次静脉给药5.7g/m2,输注时间在30分钟"}, {"probability": {"variance": 5e-06, "average": 0.998681, "min": 0.98973}, "location": {"width": 833, "top": 1218, "height": 62, "left": 210}, "words": "以上,每两周一次,所产生的毒性反应是临床上可接受的。临床一旦怀疑有过量情况,应对"}, {"probability": {"variance": 1e-06, "average": 0.99914, "min": 0.994193}, "location": {"width": 528, "top": 1267, "height": 53, "left": 211}, "words": "血液学指标进行适当的监测,必要时对病人进行支持治疗"}, {"probability": {"variance": 5e-06, "average": 0.998494, "min": 0.993667}, "location": {"width": 119, "top": 1319, "height": 29, "left": 239}, "words": "【药理毒理】"}, {"probability": {"variance": 3.7e-05, "average": 0.996632, "min": 0.963759}, "location": {"width": 812, "top": 1346, "height": 62, "left": 235}, "words": "本品是细胞周期特异性抗代谢类抗癌药,主要杀伤DNA合成期(s期)细胞,也可以阻"}, {"probability": {"variance": 0, "average": 0.99916, "min": 0.998824}, "location": {"width": 92, "top": 1348, "height": 32, "left": 233}, "words": "药理作用"}, {"probability": {"variance": 0.003054, "average": 0.982905, "min": 0.657867}, "location": {"width": 836, "top": 1373, "height": 64, "left": 214}, "words": "断细胞由GI期向S期进展。本品在细胞内经核苷激酶转化为具有活性的二磷酸盐( dfdcdp)"}, {"probability": {"variance": 0.001461, "average": 0.985461, "min": 0.8246}, "location": {"width": 833, "top": 1402, "height": 62, "left": 217}, "words": "和三磷酸盐( dfdctp),抑制DNA的合成。一方面, dfdcdp抑制核苷酸还原酶,使合成"}, {"probability": {"variance": 0.001614, "average": 0.983753, "min": 0.822074}, "location": {"width": 833, "top": 1430, "height": 61, "left": 215}, "words": "DNA必需的三磷酸脱氧核苷(包括dCTP在内)生成减少。另一方面, dfdctp与dCTP竞"}, {"probability": {"variance": 0.001966, "average": 0.981639, "min": 0.771313}, "location": {"width": 828, "top": 1460, "height": 58, "left": 218}, "words": "争掺入DNA分子中,而细胞内dCTP浓度的降低更加促进 dfdctp向DNA的掺入。 dfdctp"}, {"probability": {"variance": 0.001588, "average": 0.979217, "min": 0.830009}, "location": {"width": 834, "top": 1486, "height": 63, "left": 216}, "words": "掺入DNA后,由于DNA聚合酶不能去除掺入的 dfdctp而修复延伸中的DNA链,在延"}, {"probability": {"variance": 0.000647, "average": 0.986522, "min": 0.881429}, "location": {"width": 833, "top": 1514, "height": 60, "left": 218}, "words": "伸链中掺入的 dfdctp可进一步抑制DNA合成。本品可使CEM(慢性红系骨髓增生症)的"}], "language": 3}